Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint

Ethan M. Basch, Mark Scholz, Johann S. de Bono, Nicholas Vogelzang, Paul de Souza, Gavin Marx, Ulka Vaishampayan, Saby George, James K. Schwarz, Emmanuel S. Antonarakis, Joseph M. O'Sullivan, Arash Rezazadeh Kalebasty, Kim N. Chi, Robert Dreicer, Thomas E. Hutson, Amylou C. Dueck, Antonia V. Bennett, Erica Dayan, Milan Mangeshkar, Jaymes HollandAaron L. Weitzman, Howard I. Scher

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Fingerprint

Dive into the research topics of 'Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint'. Together they form a unique fingerprint.

Medicine & Life Sciences